title: Six-drug sequential chemotherapy in non small cell lung cancer. A North Milan Group Study.
abstract: Forty-five patients with inoperable non small cell lung carcinoma were treated according to a sequential polychemotherapeutic regimen with cisplatin-vinblastine (A), cyclophosphamide-etoposide (B), and adriamycin-vincristine (C). Patients were evaluated every two cycles. Ten patients (22.2%) showed a partial response with a mean duration of 20 weeks, and mean survival of 50.8 weeks. It is remarkable that, among them, 6 patients (13.3%) lived over 12 months and three (6.6%) over 18 months. The mean survival for all patients was 35.7 weeks. Toxicity was acceptable and reversible.
authors.affiliation: Clinica Medica, Università degli Studi di Milano, Italia.
authors.forename: M T
authors.initials: MT
authors.lastname: Cattaneo
authors.forename: G
authors.initials: G
authors.lastname: Vago
authors.forename: E
authors.initials: E
authors.lastname: Piazza
authors.forename: V
authors.initials: V
authors.lastname: Filipazzi
authors.forename: M
authors.initials: M
authors.lastname: Maruzzi
authors.forename: B
authors.initials: B
authors.lastname: Rho
authors.forename: A
authors.initials: A
authors.lastname: Silvani
authors.forename: F
authors.initials: F
authors.lastname: De Marinis
authors.forename: R
authors.initials: R
authors.lastname: Cogo
authors.forename: M P
authors.initials: MP
authors.lastname: Calzavara
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged